BETA vs CORONA: Stock Comparison

Beta Drugs Ltd vs Corona Remedies Ltd

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Corona Remedies Ltd is the larger company by market capitalisation. Beta Drugs Ltd shows a lower P/E, while Corona Remedies Ltd shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Beta Drugs Ltd and Corona Remedies Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BETA is more favourable on 3 of 13 scored metrics and CORONA on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CORONA is the larger company
₹12,934 Cr vs ₹2,558 Cr
P/E Ratio
BETA has a lower P/E
57.18x vs 69.21x
P/B Ratio
BETA has a lower P/B
9.69x vs 17.16x
EPS
BETA has higher earnings per share
₹40.9 vs ₹30.3
Dividend Yield
CORONA has a higher dividend yield
0.49% vs 0%
Qtr Sales Growth
CORONA has stronger quarterly sales growth
20.2% vs 0.21%
Qtr Profit Growth
CORONA has stronger quarterly profit growth
43.7% vs -15.2%
ROE
CORONA has a higher ROE
29.5% vs 18.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricBETACORONA
Live Price₹2,315.6₹2,113
Day Change1.69%4.1%
Volume19,16461,596
52-Week High₹2,674₹2,128.4
52-Week Low₹990.1₹1,336.6
Distance from 52W High-13.4%-0.72%

Valuation

MetricBETACORONA
Market Cap₹2,558 Cr₹12,934 Cr
P/E Ratio57.18x69.21x
P/B Ratio9.69x17.16x
EPS₹40.9₹30.3
Book Value₹241₹122
Dividend Yield0%0.49%

Growth

MetricBETACORONA
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0.21%20.2%
Qtr Profit Growth-15.2%43.7%

Profitability & Leverage

MetricBETACORONA
ROE18.8%29.5%
ROCE19.2%33.3%
Net Margin10.78%13.19%
Operating Margin19.7%21%
Debt to Equity0.6x0.22x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBETACORONA
Promoter Holding59.1% 5.53 pp69%
FII Holding1.02% 0.14 pp3.63% 1.38 pp
DII Holding6.23% 4.08 pp12.9% 5.88 pp
Public Holding33.65% 1.59 pp14.48% 7.26 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Beta Drugs Ltd and Corona Remedies Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.